Evidence map›Paper›PMID 42174625›Full record

ArticleBiology direct2026

Naringin and hesperidin protect ovarian granulosa cells from cisplatin-induced mitochondrial dysfunction by enhancing bioenergetics and mitophagy.

Jiying Liu, Ekramy M Elmorsy, Ahmed Abdeen, Nuha Anajirih, Farouk S Elgendy, Heba M Abdelkareem, Hend E Nasr, Sania K Elwia, Mai A Sherif, Noha O El-Shaer and 7 more

Abstract read
In one paragraph

Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jiying Liu *The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121000, China.
Ekramy M Elmorsy *Center for Health Research, Northern Border University, Arar, 91431, Saudi Arabia. ekramy.elmorsy@nbu.edu.sa.
Ahmed AbdeenDepartment of Biochemistry, Faculty of Veterinary Medicine, Qena University, Qena, 83523, Egypt.
Nuha AnajirihDepartment of Emergency Medical Services, Faculty of Health Sciences, Al Qunfudhah, Umm Al-Qura University, Makkah, 21912, Saudi Arabia.
Farouk S ElgendyDepartment of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Heba M AbdelkareemDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Hend E NasrDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Sania K ElwiaDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Mai A SherifDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Noha O El-ShaerDepartment of Physiology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Hend S El-WakeelDepartment of Physiology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Mustafa ShukryDepartment of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Saudi Arabia, Al-Ahsa, 31982, Saudi Arabia. matta@kfu.edu.sa.
Samah F IbrahimDepartment of Internal Medicine, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
Shaymaa AliDepartment of Pharmacology, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Mohammed A GebbaDepartment of Oral Surgery and Diagnostic Sciences, Faculty of Dentistry, Applied Science Private University, Amman, Jordan.
Amal S Abu-AlmakaremDepartment of Basic Medical Sciences, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha, 65525, Saudi Arabia.
Qingda GeThe First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121000, China. gqd334880887@163.com.

Funding

King Faisal University KFU KFU261460Northern Borders University NBU-CRP-2025-2510Princess Nourah Bint Abdulrahman University PNUR¬SP2026R127
6 · The paper itself

Abstract

backgroundCisplatin (CDDP) is a widely deployed chemotherapeutic medication used to treat various solid tumors, but its clinical utility is limited by dose-dependent ovarian toxicity. Naringin (NG) and hesperidin (HD) are two naturally occurring flavonoids found in citrus fruits and have protective effects on mitochondrial function.

resultsThe current study examined the protective effects of NG and HD on CDDP-induced mitochondrial dysfunction and cytotoxicity in granulosa cells. The cells are treated with CDDP alone or with NG or HD. CDDP reduced cell viability, ATP synthesis, oxygen consumption rate (OCR), mitochondrial membrane potential (MMP), and mitochondrial complex functions in a dose-dependent pattern. It also altered mitochondrial dynamics and enhanced glycolytic activity, as exhibited by lactate levels. MMF increased, and fatty acid composition changed, resulting in a higher unsaturated/saturated ratio. PINK1 and PARKIN levels were reduced upon CDDP treatment, suggesting mitophagy disruption. Co-treatment of NG and HD enhanced complex activity, MMP, OCR, ATP generation, and cell viability. MMF was protected by NG and HD, which also stabilized fatty acids and enhanced ion permeability and mitochondrial swelling. Compared to NG, HD preserved numerous attributes more effectively and restored them almost completely.

conclusionsNG and HD effectively preserve mitochondrial bioenergetics, structure, and dynamics in granulosa cells, mitigating CDDP-induced dysfunction. These findings highlight their potential as natural adjuvants to reduce ovarian toxicity and support fertility preservation in female cancer patients.

Indexed as

CisplatinEnergy MetabolismFlavanonesGranulosa CellsHesperidinMitochondriaMitophagyAnimalsCell SurvivalFemaleMembrane Potential, MitochondrialCisplatinFlavanonesHesperidinnaringinBioenergeticsChemotherapyMitochondrial complexesMitochondrial membrane potentialMitophagyMolecular dockingPINK1/PARKIN pathway

Identifiers

PMID42174625
PMCPMC13348574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.